New this year, we’re co-locating our event with The MedTech Conference powered by AdvaMed, to San Jose, CA!

Join us for this important program that dives into the changing landscape and the issues facing our pathway to greater innovation. This year’s theme is “Partnering for Breakthroughs in Pediatric Surgery and Care.”

Albeit small, Baltimore’s startup community is a thriving one. Just 45 minutes outside of the District, the city’s innovation scene is rich with opportunity and talent.

Maybe that’s why Baltimore is one of the most successful places working with Venture for America, a two-year salaried fellowship program that matches recent college grads with startups in 18 different cities.

Over the past year, Johns Hopkins University has played an integral role in bringing a nationwide program designed to boost small businesses to Baltimore and helping it flourish.

Today, program partners Goldman Sachs and Bloomberg Philanthropies announced a five-year, $10 million commitment to continue the program in Baltimore and named JHU the host site.

As Inova Health System prepares to open its new personalized health accelerator this fall, startups recently learned the terms of winning a spot there.

Inova plans to offer $75,000 in funding in exchange for 10 percent equity in early-stage companies selected to join the accelerator, Managing Director Hooks Johnston told an audience at a D.C. event last week. Johnston went on to say, according to Technical.ly DC, companies that make it through an individualized program for four or five months and can get $250,000 in third-party commitments can receive an Inova match.

Scientists for the first time have successfully edited genes in human embryos to repair a common and serious disease-causing mutation, producing apparently healthy embryos, according to a study published on Wednesday.

Tue, December 12, 20174:30 PM – 8:00 PM EST

Join more than 400 of the region’s business, government and community leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, December 12, 2017 at M&T Bank Stadium. As we celebrate our 20th Anniversary, we will take a look back at the success and growth that the region has experienced over the last two decades, while also featuring Greater Baltimore’s future as a global leader. As we celebrate the results of longstanding partnerships that have led to Baltimore’s economic success, we look forward to celebrating the visionaries and leaders who will shape our tomorrow.

The Precision Medicine Policy and Ethics Conference is a forum for national and industry leaders to address the most pressing challenges in the clinical adoption and integration of genomic medicine. The discussion will take place before an audience of providers, policymakers, scientists and academics. Programming for the conference will examine the ethical and regulatory issues surrounding this topic, including integrating precision medicine into physician education and practice, demographic and socioeconomic barriers to widespread access, and the role and rights of patients concerning genetic data.

MedImmune and Sanofi Pasteur are creating and marketing MEDI8897, a drug that aims to prevent lower respiratory tract illnesses that stem from respiratory syncytial virus.

Respiratory syncytial virus, which has symptoms that are related to colds, leads the way when it comes to what gives children and infants lower respiratory tract illness.

The Emmes Corporation today announced that it was awarded a contract from the National Institutes of Health to support pediatric clinical trials sponsored by the National Institute of Child Health and Human Development (NICHD). Valued at nearly $70 million, the 10-1/2 year contract will support the NIH's effort to improve the labeling of drugs for pediatric use.

On Thursday, FDA commissioner Scott Gottlieb announced a pilot program to look into a "pre-certification" for medical software start-ups.

And even the FDA's harshest critics are excited about it.

It’s an exciting time to be in Montgomery County. Discover the diverse tapestry of business success in the We Are Montgomery County video series, and consider sharing your unique perspective with us. From our highly-educated talent and regional connectivity to our culturally rich communities and superb quality of life, there’s no better time to be in MoCo.

Georgetown University's MS in Biotechnology Program seeks biotech companies and labs to provide internships. If you have a project that's been on the back burner, this is a great opportunity to get it done with quality and qualified interns at no cost to you.

For more information, check out the flyer below and/or contact: Vasna Nontanovan, MS Associate Dir. and Internship Course Dir. This email address is being protected from spambots. You need JavaScript enabled to view it. or 202-687-6136

Keiretsu Forum Mid-Atlantic Cordially Invites You to Attend Our August 2017 Meetings

Featuring Entrepreneurs and Companies from Technology-(Internet, Software, Security, SaaS, Mobile Systems, etc.), Life Sciences-Pharma-Medical Devices, Consumer Products, Real Estate, & more!

Keiretsu Forum is the world’s largest private equity angel investment network with more than 1350+ accredited investors in 31 North American chapters and 1000+ investors in 21 international chapters, who have invested more than $850m+ in early stage companies in the last 17 years.

Join peers, thought leaders, venture capitalists, and angel investors at this month's Keiretsu Forum Meeting and see for yourself why Keiretsu Forum is a major force in Private Equity-Angel Investing today.

The Fort Detrick Alliance, in partnership with the Frederick Innovative Technology Center, Inc., will host a Technology Showcase

September 6, 2017 - 4:30 p.m. - 7:30 p.m.

Join us for an evening of networking, innovative technology demonstrations, and a tour of Frederick County's only business incubator and accelerator, FITCI.  This event promises to be an exciting opportunity.  Learn about the newest technologies to come into the marketplace and meet with the companies developing them!

Last November, Pharmaceutical Online had the privilege of visiting GSK’s U.S. global R&D hub in Upper Providence, Pa. The 1.4-million sq. ft. facility will soon house the company’s consolidated U.S. R&D activities across the areas of HIV and infectious disease, oncology, immune-inflammation, metabolic pathways and cardiovascular, and dermatology. By 2018, it will be home to more than 3,200 employees, who will collaborate on target identification, safety studies, active pharmaceutical ingredient (API) manufacture, and many other R&D-related activities.

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote delivery. Emergent’s device is being designed for intramuscular self- or buddy-administration of antidotes for use in military environments and for civilian emergencies.

Adam Havey, executive vice president, business operations at Emergent BioSolutions, said, “Ease of use and rapid delivery of antidotes are critical features of auto-injectors that are intended to mitigate the health effects of nerve agent exposure. Emergent’s device seeks to satisfy the requirements of the Department of Defense for a novel auto-injector platform technology, and we look forward to collaborating with our development partners to meet the DoD’s needs.”

AstraZeneca (LSE: AZN) and its research arm MedImmune, today announced the appointment of two internationally-recognized immuno-oncology leaders.

Dr Jean-Charles Soria joins MedImmune as senior vice president, head of oncology innovative medicines, and Dr Geoffrey Kim has been appointed as head of oncology strategic combinations at AstraZeneca.

Bala Deshpande, India head of US venture capital fund NEA, is setting up an independent investment firm along with her three colleagues, said three people aware of the development.

NEA (New Enterprise Associates) is a California-based global venture capital firm.

NIIMBL is pleased to announce the Quick Start Project (QSP) call. The QSP call solicits proposals for open topic, industry-wide projects focused on the NIIMBL mission of advancing biopharmaceutical manufacturing. Proposal Submission Process Details regarding the proposal submission process and required documents can be found in Section 6 of the RFP document.

After several weeks of talks, Discovery Communications Inc. has reached a deal to acquire the owner of HGTV and Travel Channel.

The Silver Spring-based company announced Monday morning that it would acquire Scripps Networks Interactive Inc. in a cash-and-stock deal valued at $14.6 billion. The transaction is valued at $90 per share — roughly a 4 percent premium on Scripps’ Friday closing price of $86.91 and a 34 percent premium on its share price since Scripps ownership began discussing a sale earlier this month.

With more than 15 years as a nonprofit professional, Amanda joins the Fort Detrick Alliance with extensive experience in communications, marketing, fundraising, event planning, public relations, and management. She replaces Eileen Mitchell, who served as Executive Director since December 2015 In her career, Amanda served as the Assistant Director at the Historical Society of Frederick County; Marketing Manager at the National Shrine of Saint Elizabeth Ann Seton; Marketing director of Black Rock Center for the Arts; and Public Relations Specialist at the University System of Maryland at Hagerstown. Amanda has been instrumental in tourism marketing in the region and served for four years on the Tourism Council of Frederick County's marketing and group sales committees. As a writer and journalist, Amanda published articles in Frederick Magazine, Find It Frederick magazine, Eastern Home and Travel, the Baltimore Sun, and other regional publications. Amanda may be reached at 301-788-9896 or email This email address is being protected from spambots. You need JavaScript enabled to view it. Thank you for your continued support of Fort Detrick and the Alliance. We hope to see you at one of our events. If you are interested in becoming a member of the Alliance, please feel free to contact me at This email address is being protected from spambots. You need JavaScript enabled to view it..

Sincerely,

Amanda Johnston Executive Director 

BHI Q&A with 3i Diagnostics, Inc. President & CEO, Jim Janicki & Chief Technology Officer, Rajesh Krishnamurthy

Company: 3i Diagnostics, Inc. “3iDx” www.3iDx.com

Location: Germantown Innovation Center/Launch Labs

Founded: 2013

Overview: 3iDx is an early stage company developing a new technology platform that is able to isolate and analyze microbes directly from samples for the purpose of identifying antimicrobial resistant strains in less than an hour without having to wait for up to a week for blood culture results. Their ultimate aim is to create a 15-minute test that runs in a battery powered handheld device.

AstraZeneca and MedImmune, have today announced  that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy.

GlaxoSmithKline (GSK) is axing 130 'non-core' brands and overhauling its prescription drugs business to focus on products that deliver stronger returns.

It is also stepping up a cost reduction program that has already bitten into media and marketing budgets across the consumer healthcare portfolio.

AstraZeneca and Merck & Co. announced on July 27, 2017 that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor for treating BRCA-mutated ovarian cancer in multiple lines of treatment. It was approved by FDA in December 2014 and generated 2016 sales of $218 million.

The Inova Personalized Health Accelerator (IPHA) is preparing to accept applications from early-stage startups focused on predicting, preventing and treating disease. Falls Church-based Inova Health System announced plans for the accelerator last December when it also launched Inova Strategic Investments, a venture-capital program. Both projects are housed at the new Inova Center for Personalized Health, a 117-acre campus in Fairfax County.

The road to launching a life science start-up can be a long and difficult one, with founders often struggling to secure funding and manage the logistics of setting up a business. In a move to encourage innovation and help start-ups hit the ground running, there are an increasing choice of accelerator and support programs becoming available.

We spoke to Giovanni Rizzo, PhD MBA Chief of Innovation Division, Z-Cube S.r.l. to learn more about such programs and the difference they can make to innovation, as well as share some tips for academics beginning a start-up venture. 

Sucampo’s (NASDAQ:SCMP) share price has been stuck in a range for a considerable time, but the company wasn’t idle - management has been working hard to move the company away from its legacy product Amitiza into rare diseases. Sucampo made two transactions since early 2016 and now has two late-stage orphan assets (one wholly owned and an option on the other) with data readouts in 2018. Sucampo is generating strong free cash flow and expects to continue to build out its late-stage orphan drug pipeline. Meanwhile, Amitiza has been growing at a steady pace and that’s despite the growing competition in the constipation space. I believe that cash flow from Amitiza provides downside protection while the orphan pipeline stands to add significant value in the long run.

Tuesday, August 22, 2017 from 8:30 AM to 10:30 AM

The MITRE Corporation, BHI, and Montgomery County Economic Development Corporation are pleased to announce the Innovation Bridge Breakfast Series at the Rockville Innovation Center. We hope you will join us for the first in a quarterly series of technology talks, geared to foster innovation and create connections among the regional entrepreneurial community.Sign-up soon! Registration is limited.

As the White House and the US Congress continue to lock horns over President Donald Trump's proposed budget, scientists are once again anxious about funding levels. But more money is not enough to create better science. Indeed, the scientific enterprise has been betrayed by the mismanagement of its financial support.

In the craft-beer industry, the majority of hops — the flowers used in production that add bitterness and aroma to the product — come from the Pacific Northwest region.

Could Maryland, too, be a fertile region for hops?

GlaxoSmithKline will cut more than 30 drug development programmes and may sell its rare diseases unit, as the FTSE 100 group seeks to inject more “edge and pace” into its decision making, its new chief executive Emma Walmsley has said.

The day after emocha® Mobile Health, Inc., launched in 2013, CEO Sebastian Seiguer (pronounced SAY-ger) heard about a 3-year-old tuberculosis (TB) patient being treated at a Baltimore clinic. Maryland requires healthcare providers to watch patients take every dose of their medication for active TB treatment, an approach known as directly observed therapy (DOT). But coordinating with the clinic every day was proving too difficult for the girl's mother to manage. To keep up with the treatments, she would have had to quit her job.

No area is hotter or attracting more dollars in pharma than immuno-oncology–the idea of harnessing the immune system to fight cancer. My fellow Forbes contributor Bruce Booth has recently characterized the intensifying interest in this space as the “exploding supernova” of cancer research.

Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. ZIKV-VLA1601, which has shown to elicit functional antibody responses, is based on Valneva's established inactivated, whole virus manufacturing platform on which its licensed Japanese Encephalitis vaccine was developed and produced.